Elequin Capital’s Insmed INSM Stock Holding History

Elequin Capital’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-407	Closed	-$28.1K	–	473
2024 Q4	$28.1K	Buy	+407	New	+$29.3K	﹤0.01%	216
2023 Q3	–	Sell	-259	Closed	-$5.46K	–	502
2023 Q2	$5.46K	Buy	+259	New	+$4.91K	﹤0.01%	360
2022 Q3	–	Sell	-856	Closed	-$17K	–	612
2022 Q2	$17K	Buy	856 +191	+29%	+$4K	﹤0.01%	203
2022 Q1	$16K	Buy	+665	New	+$15.5K	﹤0.01%	138

Other funds holding INSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Elequin Capital's INSM Position: Q1 2025 in Review

Elequin Capital sold out of Insmed (INSM) in Q1 2025, closing a stake of 407 shares — an estimated $28.1K sold.

Elequin Capital first reported a position in INSM in Q1 2022 and held it in 4 quarters. The position peaked at $28.1K in Q4 2024. 441 funds tracked by Wall St. Rank hold INSM as of Q1 2025.

Elequin Capital reported no remaining Insmed position as of Q1 2025 after selling out during the quarter.
Elequin Capital sold 407 Insmed shares in Q1 2025, an estimated $28.1K.
Elequin Capital first reported a position in Insmed in Q1 2022 and held it in 4 quarters.
Elequin Capital's Insmed position peaked at $28.1K in Q4 2024.
441 funds tracked by Wall St. Rank held Insmed as of Q1 2025.

Based on Elequin Capital's 13F filing for Q1 2025, filed 13 May 2025.